none

PRELIMINARY BID FOR AUSSIE CANCER DRUG

01-03-2018
by 
in 

International pharmaceuticals company Merck has made an aquisition bid for Aussie firm Viralytics, after their drug Cavatak showed promising results in preliminary treatments. 

Viralytics CEO Malcolm McColl said the drug was actually a type of common cold virus that had been found to kill cancer cells, and that Cavatak was most effective when used in conjunction with Merck's immune-boosting drug Keytruda.

As a company, Viralytics centers is research around the development and commercialisation of treatments that harness the power of specific viruses to infect and kill cancer cells.

"The way we tackle cancer now is quite different to ten years ago," said McColl.

"People are looking to turn the patient's immune system against the cancer and that's really what Cavatak is doing."

Even before completion of the bid, trials have begun for testing Cavatak with Merck's Keytruda to treat melanoma, prostate, lung and bladder cancers.

Investors and the Viralytics board have positive views on the bid, viewing it as a strong opportunity for the Australian-based Viralytics to expand its reach and impact. 

"It's a good deal but we have done the hard yards on this company," said Troy Cairns, director of Viralytics investor Quest. 

"It's valuable, but its not easy to to commercialise things in Australia, and Merck is a good partner."

"Merck has done a lot of diligence on the program both in terms of the clinical and manufacturing data and are obviously fully satisfied and convinced that there's a great potential for Cavatak to help cancer patients," Mr McColl said.

 

Related news & editorials

  1. 25.03.2019
    25.03.2019
    by      In
    Following the awarding of the contract to provide the Australian Government’s Short Range Ground Based Air Defence programme, Raytheon Australia is set to build its first Australian production facility in Adelaide.
    The air defence programme, dubbed LAND19 Phase 7B, will see Raytheon Australia and... Read More
  2. 22.03.2019
    22.03.2019
    by      In
    OMAX Corporation, a manufacturer of abrasive waterjet systems, plans to join forces with Hypertherm, a manufacturer of industrial cutting systems and software, following the signing of a definitive merger agreement that establishes OMAX as a wholly owned subsidiary of Hypertherm.
    When the agreement... Read More
  3. 22.03.2019
    22.03.2019
    by      In
    CSIRO research into the Melbourne to Brisbane Inland Rail project has found that shifting horticulture and processed agriculture, such as meat, rice and dairy products, from road to rail could reduce transport costs for the agricultural sector by an estimated $70 million per year.
    Last year,... Read More
  4. 22.03.2019
    22.03.2019
    by      In
    The executive board of German bearings manufacturer Schaeffler AG has made appointments based on decisions by the company’s supervisory board on 1st March 2019. The executive board will continue to consist of eight managing directors and the four regional CEOs, but the new appointees will make the... Read More